Theriva Biologics Inc (SYN)


Stock Price Forecast

Nov. 1, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Theriva Biologics Inc chart...

About the Company

Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

CEO

Steven Shallcross

Exchange

NYSE MKT LLC

Website

www.syntheticbiologics.com

$3B

Total Revenue

10

Employees

$12M

Market Capitalization

-2.07

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SYN News

Theriva Biologics, Inc.

2mon ago, source: CNN

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product ...

Synthetic Biologics (NYSEMKT: SYN)

3d ago, source: The Motley Fool

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product ...

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

7d ago, source:

Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat ...

How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need

5d ago, source: Benzinga.com

Theriva Biologics TOVX is a biotech company that is looking to use adenoviruses to help treat pancreatic cancer. Adenoviruses are a class of viruses with an established safety profile.

Theriva Biologics (TOVX) Earnings Dates & Reports

6d ago, source: Investing

View upcoming earnings forecasts and in-depth analysis of company forecasts.

IVBIY Innovent Biologics, Inc.

14d ago, source: Seeking Alpha

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and ...

AbCellera Biologics (NASDAQ: ABCL)

3d ago, source: The Motley Fool

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies ...

Theriva Biologics Inc TOVX

5d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Theriva Biologics, Inc. (SFY.F)

24d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Theriva Biologics Inc SFY

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...